EMC1-AS1: A Potential Drug Target and Biomarker (G101927895)

Target Name: EMC1-AS1

NCBI ID: G101927895

EMC1-AS1

Other Name(s): EMC1-AS1 variant 1 | EMC1 antisense RNA 1

EMC1-AS1: A Potential Drug Target and Biomarker

EMC1-AS1 (EMC1-AS1 variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the EMC family of proteins, which are known for their role in cell signaling and communication. The EMC family of proteins have been implicated in a wide range of physiological processes, including cell adhesion, migration, and survival.

Recent studies have identified EMC1-AS1 as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology and potential clinical applications of EMC1-AS1 in more detail.

The Biology of EMC1-AS1

EMC1-AS1 is a transmembrane protein that is expressed in a variety of tissues, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the EMC family of proteins, which are characterized by the presence of a common conserved catalytic domain and a unique N-terminus. The catalytic domain is responsible for the protein's catalytic activity, while the N-terminus is involved in the protein's intracellular signaling and interaction with other proteins.

EMC1-AS1 is involved in a wide range of physiological processes that are important for the survival and function of cells. It is involved in cell adhesion and migration, which are critical processes for the development and progression of many diseases, including cancer. EMC1-AS1 is also involved in the regulation of the cytoskeleton, which is important for cell structure and stability.

In addition to its role in cell signaling and communication, EMC1-AS1 is also a potential biomarker for a variety of diseases. Its expression has been detected in a variety of tissues and has been associated with the development of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Potential Clinical Applications

The potential clinical applications of EMC1-AS1 as a drug target and biomarker are vast and varied. In cancer, EMC1-AS1 has been identified as a potential target for anti-cancer drugs because of its involvement in cell signaling and communication.

EMC1-AS1 has been shown to be involved in the regulation of cell adhesion and migration, which are critical processes for the development and progression of many cancers. Therefore, drugs that can inhibit EMC1-AS1 activity may be effective in treating a variety of cancers, including breast, ovarian, and colorectal cancers.

In neurodegenerative diseases, EMC1-AS1 has been associated with the regulation of the cytoskeleton and has been shown to play a role in the development and progression of neurodegenerative diseases. Therefore, drugs that can inhibit EMC1-AS1 activity may be effective in treating a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In autoimmune disorders, EMC1-AS1 has been shown to be involved in the regulation of immune cell function and has been associated with the development and progression of autoimmune disorders. Therefore, drugs that can inhibit EMC1-AS1 activity may be effective in treating a variety of autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, and lupus.

Conclusion

EMC1-AS1 is a protein that is expressed in various tissues of the body and is involved in a wide range of physiological processes that are important for the survival and function of cells. Its potential clinical applications as a drug target and biomarker are vast and varied, including the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the biology and clinical applications of EMC1-AS1, and to develop safe and effective drugs that can inhibit its activity.

Protein Name: EMC1 Antisense RNA 1

The "EMC1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EMC1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets